Peer-Reviewed Publication
bioRxiv2025August 12, 2025Journal Article
Structure-Activity Relationship Studies Towards Analogues of Pleconaril as Novel Enterovirus-D68 Capsid-Targeting Antivirals.
David L Cousins1,2, Ed J Griffen1,2, Jessica Stacey1,2, Alpha A Lee3,2, Yuliia Filimonova4, Anton Hlavin4, Yuliia Holota4, Roman Khmil4, Mykyta Kordubailo4, Oleksii Kostinov4, Dmytro Lesyk4, Ivan Logvinenko4, Mariia Lototska4, Viacheslav Lysenko4, Anna Pashchenko4, Mariia Pavlichenko4, Anzhela Rodnichenko4, Anton Tkachenko4, Brett L Hurst5, Justin G Julander5, Hong Wang5, Rebecca Pearl6,2, Jared Benjamin6,2, Randy Diaz-Tapia6,2, Mary E Gordon6,2, Randy A Albrecht6,2, Kris White6,2
1MedChemica Consultancy Ltd, Macclesfield, Cheshire, SK11 6DU, UK.
2The ASAP Discovery Consortium.
3PostEra, 1 Broadway, 14th floor, Cambridge, MA 02142, USA.
4Enamine Ltd., Winston Churchill Street 78, Kyiv, 02094 Ukraine.
5Institute for Antiviral Research, Utah State University, Logan, UT 84322, USA.
6Department of Microbiology, Global Health and Emerging Pathogens Institute, Icahn, School of Medicine at Mount Sinai, New York, NY, USA.
Abstract
Non-polio enteroviruses (NPEV) such as enterovirus D68 (EV-D68) that are highly infectious and associated with polio-like neurological complications have caused outbreaks, globally, in recent years. While some clinical and preclinical compounds have shown efficacy against NPEV in-vitro, liabilities that caused historical compounds such as pleconaril to fall short of FDA approval still remain. We p…
Create a free account to keep reading
Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.
Want unlimited research access? See Pro plans